Stock Events

Stock Events

FibroBiologics 

0
29
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q1 2026
Q2 2026
Next
-1.14
-0.94
-0.74
-0.54
Expected EPS
-0.541926
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2022
2023
2024
2025
0Revenue
-16.23MNet Income

Analyst Ratings

4.55Average Price Target
The highest estimate is 4.55.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SG0.MU. It's not an investment recommendation.
NVIDIA
7
NVDA
Apple
5
AAPL
Microsoft
5
MSFT
Tesla
5
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is involved in developing therapies for various diseases, including those related to fibrosis, which directly competes with FibroBiologics' focus on fibrotic diseases and regenerative medicine.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a strong presence in developing treatments for fibrotic diseases, particularly in liver fibrosis, positioning it as a direct competitor in the fibrosis therapy market.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals focuses on treating cystic fibrosis and other diseases that involve fibrotic processes, making it a key competitor in the fibrosis therapeutic area.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, including treatments for fibrotic diseases, competing in the same biologic space as FibroBiologics.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb develops various drugs for fibrotic diseases, including NASH, which overlaps with FibroBiologics' therapeutic areas.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie works on several biologic drugs that target inflammatory and fibrotic diseases, areas that are also key focuses for FibroBiologics.
Novartis
NVS
Mkt Cap292.35B
Novartis offers medications for multiple sclerosis and other chronic diseases involving fibrosis, competing in the same market as FibroBiologics.
AMGEN
AMGN
Mkt Cap233.78B
Amgen produces biologics that treat various fibrotic conditions, directly competing with FibroBiologics in the biotechnology and pharmaceutical sectors.
Merck
MRK
Mkt Cap366B
Merck & Co. develops treatments for chronic diseases that can involve fibrotic complications, positioning it as a competitor in the fibrosis treatment market.
Sanofi
SNY
Mkt Cap107.39B
Sanofi focuses on therapies for fibrotic diseases and other chronic conditions, making it a competitor in the same therapeutic areas as FibroBiologics.

About

FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
Show more...
CEO
Peter O'Heeron
Employees
15
Country
United States
ISIN
US31573L1052
WKN
000A426UV

Listings

F
DE
SG00.F
STU
DE
SG00.STU
MU
DE
SG0.MU
MU
DE
SG00.MU

0 Comments

Share your thoughts

FAQ

What is FibroBiologics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange FibroBiologics stocks are traded under the ticker SG0.MU.
When is the next FibroBiologics earnings date?▼
FibroBiologics is going to release the next earnings report on November 17, 2026.
What were FibroBiologics earnings last quarter?▼
SG0.MU earnings for the last quarter are -0.57 EUR per share, whereas the estimation was -0.81 EUR resulting in a +29.03% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is FibroBiologics revenue for the last year?▼
FibroBiologics revenue for the last year amounts to 0 EUR.
What is FibroBiologics net income for the last year?▼
SG0.MU net income for the last year is -16.23M EUR.
How many employees does FibroBiologics have?▼
As of September 04, 2026, the company has 15 employees.
In which sector is FibroBiologics located?▼
FibroBiologics operates in the Health & Wellness sector.
When did FibroBiologics complete a stock split?▼
The last stock split for FibroBiologics was on March 30, 2026 with a ratio of 1:20.
Where is FibroBiologics headquartered?▼
FibroBiologics is headquartered in HOUSTON, United States.